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Abstract
Fatty acid oxidation is an important energy source for the oocyte; however, little is known about how this metabolic
pathway is regulated in cumulus-oocyte complexes. Analysis of genes involved in fatty acid oxidation showed that many are
regulated by the luteinizing hormone surge during in vivo maturation, including acyl-CoA synthetases, carnitine
transporters, acyl-CoA dehydrogenases and acetyl-CoA transferase, but that many are dysregulated when cumulus-oocyte
complexes are matured under in vitro maturation conditions using follicle stimulating hormone and epidermal growth
factor. Fatty acid oxidation, measured as production of 3H2O from [
3H]palmitic acid, occurs in mouse cumulus-oocyte
complexes in response to the luteinizing hormone surge but is significantly reduced in cumulus-oocyte complexes matured
in vitro. Thus we sought to determine whether fatty acid oxidation in cumulus-oocyte complexes could be modulated
during in vitro maturation by lipid metabolism regulators, namely peroxisome proliferator activated receptor (PPAR)
agonists bezafibrate and rosiglitazone. Bezafibrate showed no effect with increasing dose, while rosiglitazone dose
dependently inhibited fatty acid oxidation in cumulus-oocyte complexes during in vitro maturation. To determine the
impact of rosiglitazone on oocyte developmental competence, cumulus-oocyte complexes were treated with rosiglitazone
during in vitro maturation and gene expression, oocyte mitochondrial activity and embryo development following in vitro
fertilization were assessed. Rosiglitazone restored Acsl1, Cpt1b and Acaa2 levels in cumulus-oocyte complexes and increased
oocyte mitochondrial membrane potential yet resulted in significantly fewer embryos reaching the morula and hatching
blastocyst stages. Thus fatty acid oxidation is increased in cumulus-oocyte complexes matured in vivo and deficient during
in vitro maturation, a known model of poor oocyte quality. That rosiglitazone further decreased fatty acid oxidation during
in vitro maturation and resulted in poor embryo development points to the developmental importance of fatty acid
oxidation and the need for it to be optimized during in vitro maturation to improve this reproductive technology.
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Introduction
Oocytes acquire their developmental competence, the ability to
undergo successful fertilization and development into an embryo,
during ovarian folliculogenesis. Ovarian follicle growth begins
from the primordial stage where a small oocyte is surrounded by a
single layer of somatic cells known as granulosa cells. These
proliferate and differentiate until the preovulatory stage where a
fully grown oocyte is surrounded by specialized cumulus cells, a
fluid filled antral cavity and a stratified epithelial layer of granulosa
cells. The final stages of oocyte developmental competence are
acquired following a surge of luteinizing hormone (LH) from the
pituitary which signals to the preovulatory follicle, via the
granulosa cells, to ovulate. During this time maturation of the
oocyte resumes and includes meiotic progression to metaphase II
in preparation for fertilization in the oviduct.
The in vitro maturation (IVM) of oocytes involves the isolation
of an immature oocyte and companion cumulus cells, known
collectively as the cumulus oocyte complex (COC), prior to the
LH-surge, followed by hormone treatment in vitro [1,2]. Thus,
IVM occurs in the absence of the normal follicular environment
resulting in numerous deficiencies, including altered energy
metabolism, compared to in vivo matured COCs [3–5]. Oocytes
generated by IVM have poorer development following fertilization
and result in higher miscarriage rates compared to in vivo matured
oocytes [6–8]. Thus IVM is infrequently used in clinical practice
due to the poor quality of oocytes generated using this
reproductive technology. The mechanisms underlying the poor
quality following IVM are not evident; however it is understood
that cellular metabolism and metabolic rate of the oocyte and
cumulus cells are a determinant of oocyte quality [9–13] with ATP
levels within the oocyte positively correlated with developmental
potential [14].
Lipids are metabolized for the generation of ATP by the process
of fatty acid oxidation (FAO), which is emerging as an important
process in oocyte meiotic maturation [15,16] and early embryo
development [17–19]. In fact there has been much interest in up-
regulating FAO during IVM to improve oocyte quality [17,18,20–
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24]. Further, inhibition of FAO during IVM is associated with
poor embryo development [17,25]. Thus, FAO plays an important
role in oocyte developmental competence, yet the normal in vivo
regulation of this metabolic pathway during COC maturation has
not been described. Further, whether COCs matured in vitro
achieve equivalent levels of FAO is not known.
Fatty acid oxidation can be modulated in numerous tissues, via
activation of peroxisome proliferator activated receptor (PPAR)
signalling pathways. PPARs are nuclear receptor transcription
factors that regulate the metabolism of lipids [26–28] and there are
three major types, PPARa [29], PPARc and PPARd [30], each of
which are endogenously activated by prostaglandins and fatty
acids [31]. Fibrates such as bezafibrate and thiazolidinediones
such rosiglitazone are potent pharmaceutical activators of PPARa
and PPARc, respectively [32]. We have previously shown that in
vivo administration of rosiglitazone in the periovulatory period
was able to reverse the negative effects of obesity and a high fat
diet on oocyte developmental competence in the mouse [33]. Yet
whether PPAR agonists directly affect FAO in the COC or alter
developmental competence is unknown.
Thus in the current study we sought to determine whether the
expression of genes involved in the FAO pathway are regulated in
the COC during in vivo maturation and whether similar levels are
achieved during IVM. We also determine whether FAO is
deficient during IVM using a functional assay and investigate the




All experiments were approved by the University of Adelaide’s
Animal Ethics Committee (approval number M-2009-164) and
conducted in accordance with the Australian Code of Practice for
the Care and Use of Animals for Scientific Purposes.
Materials
Equine chorionic gonadotropin (eCG) and follicle stimulating
hormone (FSH) were purchased from the National Hormone and
Peptide Program (NHPP) (Tovance, CA, USA). Human chorionic
gonadotropin (hCG; Pregnyl) was purchased from Lyppard
Australia Pty. Ltd. (Keysborough VIC). Culture medium was
purchased from Gibco, Invitrogen Australia Pty. Ltd. All other
reagents were purchased from Sigma-Aldrich Pty. Ltd. unless
otherwise indicated.
Animals
All mice were purchased from Laboratory Animal Services
(Adelaide, SA) and were maintained on a 12L:12D photoperiod
with rodent chow and water provided ad libitum.
Isolation of Mouse COCs
Prepubertal (day 21–23 of age) CBA 6 C57BL/6 first filial
generation (F1) (CBAF1) female mice were treated with intraper-
itoneal administration of eCG (5IU) alone or followed by
intraperitoneal administration of hCG (5 IU) 44–48 h later.
Ovaries were dissected from mice and placed in Hepes-buffered
minimum essential medium alpha (aMEM) containing 5% fetal
calf serum (FCS). At 46 h post eCG (immature; 0 h hCG) or 6, 10
or 16 h following administration of hCG (preovulatory; in vivo
matured), COCs were collected by puncture of large antral
follicles, or the oviduct (16 h post-hCG) with a 30-gauge needle to
release COCs. Approximately 30 COCs are obtained from each
mouse. For the in vitro maturation of COCs, immature COCs
isolated from ovaries of at least 6 mice at 46 h post-eCG were
pooled and matured for 10 or 14 h in bicarbonate buffered
Figure 1. Long chain fatty acid activation, entry into mitochondria and metabolism via fatty acid oxidation. U Entry of long chain fatty
acids into mitochondria requires activation by acyl-CoA synthetase enzymes which catalyze the transfer of CoA from CoA-SH to form fatty acyl-CoA. V
Activated fatty acids enter mitochondria via enzymatic transfer of CoA for carnitine which is catalyzed by carnitine palmitoyl transferase I (CPTI). Fatty
acyl-carnitine enters the mitochondrial matrix via carnitine acylcarnitine translocase where carnitine palmitoyl transferase II (CPTII) replaces carnitine
with CoA. This is known as the carnitine shuttle. W Fatty acyl-CoA then enters the fatty acid oxidation spiral which has 4 steps catalyzed by 1) fatty
acyl CoA dehydrogenase, 2) enoyl CoA hydratase, 3) hydroxyacyl CoA dehydrogenase and 4) acetyl-CoA transferase (also known as ketoacyl-CoA
thiolase) and yields an acetyl-CoA molecule for each cycle. X Acetyl-CoA is able to enter the tricarboxylic acid (TCA) cycle which with fatty acid
oxidation generates electrons forming NADH and FADH2 which donate electrons to the electron transport chain (ETC) required for ATP synthesis Y
Genes involved in fatty acid oxidation were measured in cumulus oocyte complexes during in vivo maturation in response to hCG. A summary of
their expression pattern is depicted with blue, red and black coloured genes representing significantly up-regulated, down-regulated and unchanged
respectively, as demonstrated in Figure 2.
doi:10.1371/journal.pone.0087327.g001
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aMEM supplemented with 5% FCS, 5 ng/ml epidermal growth
factor (EGF), 50 mIU/ml FSH, and 0.25 mM pyruvate at 37uC
and 6% CO2.
Gene Expression Analysis
In three independent experiments, COCs were isolated from 12
mice, pooled and frozen in liquid nitrogen. RNA was extracted
from COCs using the RNeasy Mini Kit (Qiagen, VIC, Australia)
as per the manufacturer’s instructions. RNA concentration and
purity were quantified using a Nanodrop ND-1000 Spectropho-
tometer (Biolab Ltd., Victoria, Australia). Reverse transcription to
cDNA was performed using 236, 300 or 114 ng of RNA (COC in
vivo maturation time course; in vivo versus IVM COC expression;
and effect of rosiglitazone on gene expression during IVM,
experiments respectively) and the RT2 First strand kit (Qiagen,
VIC, Australia) as per manufacturer’s instructions, which includes
a genomic DNA elimination step. Analysis of gene expression was
performed using a 384-well Fatty Acid Metabolism RT2 Profiler
Array (SA Biosciences, Qiagen, VIC, Australia). PCR cycling
conditions were 95uC for 10 min, followed by 40 amplification
cycles of 95uC for 15 seconds and 60uC for 1 min. The geometric
mean of at least two genes, as indicated in figure legends, were
used for normalization of data following assessment of reference
gene stability using BestKeeper [34]. Data were analyzed using the
22(DDCT) method.
b-Oxidation Assay
Fatty acid oxidation of 9,10-[3H]palmitate substrate was
determined by measuring the production of 3H2O over 4 hours
in COCs matured by IVM or in vivo for 10 h, as described [17].
COCs were isolated from 10 mice, pooled and added at 40 per
well to each well of a 96-well plate containing bicarbonate buffered
aMEM supplemented with 0.3 mM 9,10-[3H]palmitate (32.4 Ci/
mmol), 5% FCS, 0.25 mM pyruvate, 50 mIU/ml FSH, 5 ng/ml
EGF, 3 mM D-glucose and 0.25 mM L-carnitine in a final volume
of 100 ml for 4 h at 37uC/6% CO2.
To determine the effect of PPAR agonists bezafibrate and
rosiglitazone on b-oxidation in the COC during IVM, b-oxidation
was measured during COC maturation over 20 h. The PPARa
agonist, bezafibrate, was used at 0, 50, 100, 250, 500, and 800 mM
(diluent:#0.01% DMSO) and the PPARc agonist, rosiglitazone at
0, 0.5, 1, 5, 20, 50 or 100 mM (diluent: #0.01% DMSO) based on
studies in other cell types [35–40]. Twenty immature unexpanded
COCs (44–48 h eCG) were added to a well of a 96-well plate
containing bicarbonate buffered aMEM supplemented with
0.3 mM 9,10-[3H]palmitate (32.4 Ci/mmol), 5% FCS, 0.25 mM
pyruvate, 50 mIU/mlFSH, 5 ng/ml EGF, 3 mM/L D-glucose
and 0.25 mM L-carnitine and the required dose of agonist, in a
final volume of 100 ml, and incubated for 20 h at 37uC and 6%
CO2.
For b-oxidation assays each treatment was performed in either
triplicate or duplicate and duplicate blank wells containing no
COCs included for baseline subtraction. Excess 9,10-[3H]palmi-
tate was precipitated as described in [17]. The aqueous phase
(0.5 ml) was combined with 1 ml scintillation fluid and counted on
a Beckman LS 6000LL b-counter for 20 minutes. b-oxidation
levels were calculated by first subtracting the mean of the duplicate
blank wells, then dividing the ratio of labelled product (Ci) to
labelled substrate (32.4 Ci/mmol), and then calculating the
proportion of tritiated to unlabeled hydrogen atoms. All b-
oxidation data are presented as pmol palmitic acid/COC/hour.
Calculations were based on the assumptions of no loss of tritiated
water through evaporation and complete oxidation of the
radiolabeled substrate.
Assessment of Cumulus Expansion
Cumulus expansion was assessed following 14 h of IVM by an
independent assessor blinded to all treatments. The established
Vanderhyden scale was used to score the COC expansion from 0–
4 [41], with 0 indicating no expansion and 4 expansion of all layers
of cumulus cells.
Analysis of Mitochondrial Activity
Mitochondrial membrane potential in oocytes from COCs
matured in vitro for 14 h in the presence or absence of
rosiglitazone (20 mM) was determined using JC-1 (5,59,6,69-
tetrachloro-1,19,3,39-tetraethylbenzimidazolylcarbocyanine io-
dide; Invitrogen). COCs were collected following 14 h of IVM
in bicarbonate buffered aMEM supplemented with 5% FCS,
5 ng/ml EGF, 50 mIU/ml FSH, 0.25 mM pyruvate. Oocytes
were denuded using hyaluronidase (100 IU/ml) and manual
pipetting with a fine bore pipette, then stained in 6 mM JC-1
dissolved in Hepes buffered aMEM/0.2% polyvinylpyrrolidone
(PVP) for 15 mins at 37uC. Oocytes were then mounted in 3 ml
between 2 glass coverslips and separated by a spacer (Invitrogen,
secure-seal spacer, one well 13 mm diameter, 0.12 mm deep) and
imaged immediately in both green and red fluorescence channels
(Fluoview, FV10i Olympus confocal microscope). The plane of
focus in which the oocyte diameter was largest was assumed to be
the center and was selected for image capture and analysis.
Fluorescence intensity was quantified using analySIS pro
software (Olympus Australia Pty. Ltd., Mt Waverly, VIC, AU).
A region of interest (ROI), of fixed size that encompassed the
entire oocyte diameter was used to provide an average intensity of
fluorescence within the oocyte. An identical ROI was used for
each oocyte in all experiments.
In Vitro Fertilization and Embryo Development
Assessment
COCs were collected following 14 h of IVM in bicarbonate
buffered aMEM supplemented with 5% FCS, 0.25 mM pyruvate,
50 mIU/ml FSH, 5 ng/ml EGF, 3 mM D-glucose, 0.25 mM L-
carnitine and with or without rosiglitazone (20 mM). Sperm were
collected from CBA 6 C57BL/6 F1 male mice from the vas
deferens and the caudal region of the epididymis and capacitated
in bicarbonate-buffered aMEM supplemented with 3 mg/ml BSA
(fatty acid free) for 1 h at 37uC in an atmosphere of 6% CO2 and
94% air. Following capacitation, COCs and sperm were co-
incubated in bicarbonate-buffered aMEM supplemented with
3 mg/ml BSA for 4 h at 37uC in an atmosphere of 6% CO2 and
94% air. Presumptive zygotes were stripped of any remaining
cumulus cells and sperm by manual pipetting and cultured in 20 ml
drops of ‘‘Vitro Cleave’’ (A905969; COOK Australia, Brisbane,
QLD, Australia) overlaid with mineral oil. Presumptive zygotes
Figure 2. Modulation of genes involved in fatty acid oxidation in the cumulus oocyte complex during oocyte maturation in vivo.
Analysis of Acsbg2, Acsl1, Acsl4, Acsl5, Acsl6, Acsm3, Cpt1a, Acad10, Acad11, Acadl, Acadm, Acadsb, and Acaa2 (A–M, respectively) expression in
cumulus oocyte complexes at 0, 6, 10, and 16 h post-hCG administration is shown. mRNA expression was normalized to the geometric mean of Gusb,
Hprt, Actb, Gapdh and Hsp90ab1 and presented as mean6 SEM (n= 3 experimental replicates, different superscripts signify statistical difference of P,
0.05 by one-way ANOVA with Tukey post hoc test).
doi:10.1371/journal.pone.0087327.g002
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Figure 3. Gene transcripts involved in fatty acid oxidation are dysregulated in cumulus oocyte complexes matured in vitro (IVM).
Analysis of Ascbg1, Acsbg2, Acsl1, Acsl4, Acsl5, Acsl6, Acsm3, Acsm4, Cpt1b, Acad10, Acad11, Acadm, Acadsb, Acadvl, and Acaa2 (A-O, respectively)
expression in cumulus oocyte complexes following 10 h of in vivo or in vitro maturation (IVM). mRNA expression was normalized to the geometric
mean of Gapdh and Hsp90ab1 and presented as mean 6 SEM (n= 3 experimental replicates, * P,0.05, ** P,0.01, *** P,0.001 by unpaired t test).
doi:10.1371/journal.pone.0087327.g003
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were cultured at 37uC in an atmosphere of 6% CO2 and 94% air.
Fertilization rate was scored 24 hours post-insemination (day 2)
based on the division of the oocyte into a two-cell embryo. On day
three of embryo culture (48 h post-insemination), the embryos
were moved to a new 20 ml culture drop of ‘‘vitro cleave’’ medium
(A905969, Cook Medical). Embryo development was assessed on
day 3 (48 h post-insemination), 4 (78 h post-insemination) and
day 5 (96 h post-insemination) of embryo culture for development
to the 4–8 cell, $ morula and blastocyst stages of development,
respectively.
Statistical Analyses
Results are presented as the mean 6 SEM. Statistical analyses
were performed as indicated in figure legends using GraphPad
Prism Version 5.1 for Windows (GraphPad Software, Inc.). All
data were checked for normality and transformed where necessary
as indicated in the figure legends. One-way ANOVA, two-way
ANOVA, and t tests were used as described in the figure legends
and statistical significance was considered at a P value of ,0.05.
Proportional data (embryo development) were arcsine transformed
prior to statistical analysis.
Results
Temporal Expression of Genes Involved in Fatty Acid
Oxidation during Oocyte Maturation In Vivo
We first determined whether genes involved in the fatty acid
oxidation (FAO) metabolic pathway (Fig. 1) are regulated in the
COC following an ovulatory dose of hCG to induce oocyte
maturation in vivo. We analysed the expression of several isoforms
of acyl-CoA synthetases, which activate long chain fatty acids by
catalyzing their conversion to acyl CoA derivatives allowing
transport into mitochondria, and found that Acsbg2, Acsl1, Acsl4
and Acsl5 were significantly induced during oocyte maturation in
vivo while Acsl6 and Acsm3 were significantly down-regulated
(Fig. 2A–F). The expression of Acsbg1, Acsl3, Acsm2, Acsm4 and
Acsm5 were not regulated during in vivo maturation (data not
shown). Expression of carnitine transporters Cpt1a, Cpt1b, Cpt1c
and Cpt2 which transport activated long chain fatty acids into the
mitochondria revealed that Cpt1a was significantly induced
(Fig. 2G) while the other genes remained unaltered (data not
shown).
Analysis of acyl-CoA dehydrogenase isoforms, which catalyze
the first step in the FAO spiral, revealed that Acad10 and Acad11
were significantly altered post hCG demonstrating an initial down
regulation at 6 h post hCG while at 16 h, post ovulation,
expression was not significantly different from immature 0 h
COCs (Fig. 2H and I). Acadl, Acadm and Acadsb were significantly
induced in the COC during maturation in vivo (Fig. 2 J–L). The
fourth and final step in the FAO spiral is performed by acetyl-CoA
transferase and encoded by Acaa2. Acaa2 expression was signifi-
cantly up-regulated during oocyte maturation in vivo compared to
immature 0 h COCs (Fig. 2M). These results show that a number
of FAO genes are dynamically regulated in COCs in vivo in
response to ovulatory hCG and that even distinct isoforms of
similar enzymes exhibit differential expression patterns (see Fig. 1
for summary of changes).
Figure 4. FAO is reduced in cumulus oocyte complexes
matured in vitro and is modulated by rosiglitazone but not
bezafibrate. Cumulus oocytes complexes (COC) were matured for
10 h in vitro (IVM) or collected 10 h following the administration of hCG
(in vivo matured). b-oxidation was measured over 4 h of culture and
expressed as pmol palmitic acid metabolized per COC per hour (A).
Data presented as mean 6 SEM, n = 7 per treatment from 3
independent experiments, representative of 280 COCs per treatment.
***P,0.001 by unpaired t test. The effect of PPAR agonists bezafibrate
and rosiglitazone on b-oxidation was measured in COCs maturing in
vitro over 20 h in the presence of increasing doses of bezafibrate (B) or
rosiglitazone (C). Data presented as mean 6 SEM, n = 5 independent
experiments, representative of 100 COCs per group. Data analyzed by
one-way ANOVA and Tukey post hoc test, different letters signifying
statistical difference (P,0.05).
doi:10.1371/journal.pone.0087327.g004
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Fatty Acid Oxidation Pathway Genes are Dysregulated in
COCs Matured In Vitro
We next assessed whether COCs matured in vitro had altered
expression of these dynamically regulated fatty acid oxidation
genes. The time point of 10 h maturation was chosen for
comparison since the majority of genes were significantly different
at this time point in vivo compared to levels at 0 h (Fig. 2). There
was no difference in cell number between COCs from the two
maturation conditions (in vivo: 30406205.5; IVM: 24576377.3
cells/COC). Analysis of COCs matured for 10 h in vitro showed
that Acyl-CoA synthetase expression was significantly altered in
IVM COCs compared to in vivo matured COCs with Acsbg1,
Acsbg2, Acsl1, Acsl4 and Acsm3 expression significantly decreased in
IVM COCs at 10 h while Acsl5, Acsl6 and Acsm4 were significantly
higher compared to in vivo matured COCs (Fig. 3 A–H). Acsl3,
Acsm2, and Acsm3 were not different in COCs matured in vivo for
10 h compared to non-matured COCs (Fig. 2 and data not shown)
nor compared to COCs matured in vitro (data not shown).
Expression of the isoform Cpt1b was significantly reduced in IVM
COCs (Fig. 3I) while Cpt1a, Cpt1c and Cpt2 were unaltered (data
not shown). Genes encoding isoforms for acyl-CoA dehydroge-
nases which perform the first step in the FAO spiral showed
disparate expression patterns with Acad10, Acad11 and Acadvl
significantly higher in IVM COCs while Acadm and Acadsb were
significantly reduced compared to in vivo matured COCs (Fig. 3
J–N). Acadl, Acad9 and Acads expression levels were not different
between maturation treatment groups (data not shown). The
expression of the acetyl-CoA transferase Acaa2, which catalyzes the
final step in the FAO spiral, showed a significant decrease
following IVM (Fig. 3O).
We next compared functional rates of FAO in COCs that were
matured in vitro for 10 h versus COCs isolated from follicles at
10 h post-hCG (i.e. matured in vivo). There was a significant 2.8-
fold reduction in the level of FAO occurring in COCs matured in
vitro (IVM) compared to those matured in vivo (Fig. 4A). Thus,
IVM conditions result in COCs performing significantly less FAO
than in vivo matured COCs at this timepoint.
Effect of PPAR Agonists on COCs during In Vitro
Maturation
Because of the dramatically reduced level of FAO in IVM
COCs, we next determined whether agonists of PPARs, specifi-
cally bezafibrate and rosiglitazone, would increase FAO in COCs
during in vitro maturation. Real-time RT-PCR was used to
confirm the presence of Ppara, Pparg and Ppard mRNA transcripts
in COCs prior to experiments examining the effects of the PPAR
agonists (data not shown). Treatment of COCs with bezafibrate
using doses ranging from 50–800 mM had no significant effect on
FAO rate during the maturation period (Fig. 4B). At 100 mM
bezafibrate did result in a 1.4-fold increase in FAO compared to
control, however this dose also failed to have any significant effect
over control conditions in subsequent assays investigating oocyte
quality (data not shown). Conversely, treatment of COCs with
rosiglitazone during IVM significantly reduced FAO in COCs in a
dose dependant manner (Fig. 4C).
Interestingly, despite rosiglitazone treatment (20 mM) signifi-
cantly inhibiting FAO in COCs during IVM this dose caused a
significant increase in the expression of genes involved in fatty acid
Figure 5. Rosiglitazone treatment of COCs during in vitro
maturation significantly modulates expression of genes in-
volved in fatty acid oxidation. Analysis of Acsl1 (A), Cpt1b (B), Cpt1c
(C), Cpt2 (D) and Acaa2 (E) expression in cumulus-oocyte complexes
following 10 h of in vitro maturation (IVM) in the absence (0) or
presence of rosiglitazone (20 mM). mRNA expression was normalized to
the geometric mean of Gapdh and Hsp90ab1 and presented as mean 6
SEM (n = 3 experimental replicates, * P,0.05, ** P,0.01 by unpaired t
test).
doi:10.1371/journal.pone.0087327.g005
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activation (Acsl1), carnitine mediated transport (Cpt1b and Cpt2)
and the FAO spiral (Acaa2) compared to untreated controls (Fig. 5).
In contrast, expression of Cpt1c was significantly decreased in the
presence of rosiglitazone (Fig. 5C). The remaining 19 genes
measured during in vivo maturation described above (or see Fig. 1)
were also assessed but did not show significant modulation by
rosiglitazone. Rosiglitazone treatment (20 mM) also significantly
increased the degree of cumulus expansion compared to control
(cumulus expansion index: control: 3.4260.05 vs. rosiglitazone:
3.5860.05, P,0.05, Mann Whitney t test due to non-normal
distribution of data, n= 7 experimental replicates, representative
of $155 COCs per treatment).
These results show that rosiglitazone significantly inhibits FAO
in the COC during IVM despite upregulating a subset of genes
involved in the FAO metabolic pathway.
Effect of Rosiglitazone on Oocyte Quality
Oocyte mitochondrial membrane potential analyzed by JC-1
staining was altered by rosiglitazone (20 mM) during in vitro
maturation of COCs (Fig. 6 A–F). Quantification of fluorescence
confirmed that rosiglitazone treatment of COCs resulted in
oocytes with a higher red:green fluorescence ratio indicating
increased mitochondrial activity and that this was due to
significantly higher levels of both red and green
fluorescence(Fig. 6 G–I). Further, the distribution of green
fluorescence appeared altered in rosiglitazone treated COCs with
more of these mitochondria localised in the center of the oocyte
(Fig. 6E) compared to a more homogeneous distribution observed
in the oocytes matured in control conditions (Fig. 6B).
COCs matured in vitro in the presence of rosiglitazone (20 mM)
did not differ significantly in their ability to be fertilized and
develop into a 2-cell embryo compared to COCs matured under
control conditions (Fig. 7A). However, rosiglitazone treated COCs
resulted in significantly fewer morula embryos on day 4 of embryo
culture (Fig. 7A) and significantly fewer hatching blastocyst
embryos on day 5 compared to control (Fig. 7B).
Together these data show that despite rosiglitazone treatment of
COCs increasing oocyte mitochondrial membrane potential,
indicative of mitochondrial hyperpolarization, this was associated
with decreased oocyte developmental competence with fewer
fertilized oocytes capable of developing to the blastocyst stage of
preimplantation development compared to oocytes from COCs
matured in control conditions.
Discussion
Little is known about the regulation of FAO in the COC during
maturation and how it impacts subsequent embryo development.
In the current study we have shown that genes involved in FAO
Figure 6. Mitochondrial membrane potential is increased in oocytes following maturation of cumulus oocyte complexes in vitro in
the presence of rosiglitazone. Mitochondrial membrane potential was assessed by JC-1 staining of oocytes following in vitro maturation of
cumulus oocyte complexes in the absence (A–C) or presence of 20 mM rosiglitazone (D–F). Red (G), green (H) and the ratio of red:green (I)
fluorescence within oocytes was quantified and presented as mean 6 SEM, representative of 30–35 COCs per group, from 3 independent
experiments. Data analyzed by unpaired t test on untransformed (H) or Log10 transformed (G and I) data, * P,0.05; *** P,0.001.
doi:10.1371/journal.pone.0087327.g006
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are hormonally regulated in the COC during maturation in vivo
and are dysregulated during in vitro maturation. Since mature
oocytes are transcriptionally inactive and oocyte mRNA would
represent a small fraction of the mRNA in the COC, these
dynamic changes in expression levels are attributed to changes in
cumulus cells. This supports previous reports demonstrating that
b-oxidation by the oocyte represents a small fraction of that
occurring in the whole COC [16,17]. Further, using a functional
assay we show that FAO is decreased in COCs matured in vitro
compared to those that mature in vivo within the follicular
environment. Whether decreased FAO persists throughout mat-
uration in vitro remains to be determined, as does whether this
reduction is directly due to the identified alterations in gene
expression or deficiencies in other factors, such as growth factors
and specific metabolites that are lacking in in vitro systems. Lastly,
we show that treatment with the PPARc agonist, rosiglitazone,
significantly inhibits FAO and results in poor developmental
competence.
The significant upregulation of acyl-CoA synthetases Acsbg2,
Acsl1, Acsl4, and Acsl5 in the COC during maturation in vivo
indicate that the COC is preferentially utilizing fatty acids with
chain lengths of C10-C20 [42–45]. This correlates well with the
predominant forms of fatty acids present in human and bovine
follicular fluid; palmitic, oleic, linoleic and arachidonic acid [46–
49] for which Acsl1, Acsl5 and Acsl4 have high affinity [43–45].
Significant 5-fold induction of Cpt1a during maturation in vivo
indicates that there is increased capacity for carnitine-mediated
transport of fatty acids into mitochondria which is required for the
oxidation of long chain fatty acids. We have previously shown
significant upregulation of the isoform Cpt1b during COC
maturation in vivo [17] here we again saw a 2-fold increase in
Cpt1b at 10 h post-hCG though this was not statistically significant
(data not shown). However, the Cpt isoforms, Cpt1a, b and c do
not differ in their specificity for different activated fatty acids only
in their tissue localization. Thus both our previous and current
study illustrate increased Cpt1 activity indicating increased
capacity for carnitine-mediated transport of activated long chain
fatty acids into mitochondria during maturation in vivo. Acyl-CoA
dehydrogenases catalyze the first step in FAO and those encoded
by Acadl, Acadm and Acadsb have substrate optima of 16, 8, and 4
carbon chains, respectively [50,51]. Expression of these isoforms
indicate that the COC is capable of metabolizing fatty acids of 4–
16 carbons long and increases its capacity to perform FAO during
in vivo maturation. Acaa2 codes for acetyl-CoA transferase, which
catalyzes the fourth and final step in FAO, the formation of acetyl-
CoA which is able to enter the TCA cycle for ATP production.
Acaa2 was significantly induced further indicating an increased
capacity for the COC to perform FAO for energy production
during maturation in vivo.
The significant dysregulation of 15 genes in the FAO pathway
in COCs matured in vitro compared to their in vivo matured
counterparts (Fig. 3) may indicate a switch in preference of fatty
acids during the two different maturation conditions. This may be
due to the presence of different fatty acids during IVM which are
supplied via bovine serum compared to those present in the
follicular fluid in which the COC matures in vivo. It would be
interesting to examine whether supplementation of IVM media
with fatty acids found in follicular fluid normalizes the expression
level of some of the genes examined here resulting in improved
oocyte developmental competence.
Acsl4 has a particular preference for arachidonic acid, a
precursor for prostaglandin synthesis, and is involved in prosta-
glandin synthesis and release [52] with strong expression noted in
steroidogenic tissues including the ovary [44]. Thus the significant
down regulation of Acsl4 in IVM COCs observed in the current
study may be partly responsible for the poor PGE2 secretion
observed in these COCs [53] and the poorer developmental
competence of these oocytes. In support of this female Acsl4
heterozygous null mice have reduced fertility [54] as do Ptgs2
deficient mice [55].
That Acaa2, which is responsible for the final step in FAO in the
mouse, was significantly reduced in COCs matured in vitro
indicates that FAO was deficient compared to COCs matured in
vivo and this was confirmed using a functional assay. Previous
studies have shown that IVM COCs have altered mitochondrial
and glycolytic activity and poor oocyte developmental competence
[3,4]. The current study demonstrates that the down regulation of
FAO could be responsible for the subsequent developmental
deficiencies that occur in response to IVM.
Figure 7. Rosiglitazone treatment during in vitro maturation of
cumulus-oocyte complexes negatively affects oocyte develop-
mental competence. Oocyte developmental competence was
assessed following in vitro fertilization of cumulus-oocyte complexes
matured in vitro in control conditions or in the presence of rosiglitazone
(20 mM). Embryo development was assessed on days, 2, 3, 4 and 5, with
day 1 designated as the day of fertilization (A and B). Development on
day 5 was assessed as blastocyst or hatching blastocyst (B). Data
presented as mean 6 SEM, n= 7 independent experiments, represen-
tative of 132–138 oocytes per treatment group. Arcsine transformed
data were analyzed by either repeated measures two-way ANOVA (A)
or regular two-way ANOVA with Bonferroni post hoc test (B). Asterix
indicates statistical difference (P,0.05) within developmental stage.
doi:10.1371/journal.pone.0087327.g007
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The up-regulation of FAO by PPAR agonists has been reported
in many different tissues and cells, however very little attention has
been focused on their action within the ovary, especially the COC.
Both PPARa and PPARc mRNA were confirmed to be expressed
in the COCs used in these experiments (data not shown) however
it is not possible to conclude whether this includes expression
specifically in the oocyte. Bezafibrate is a potent PPARa agonist
shown to increase FAO in other cell lines and tissues [35,36].
However, in the current study bezafibrate had no effect on FAO in
the COC during in vitro maturation or on subsequent embryo
development following IVF. Rosiglitazone has been shown to
differentially modulate FAO in different cell types [56–58]. In the
current study we show that rosiglitazone treatment of COCs
during maturation in vitro dose dependently inhibited FAO
despite upregulating genes involved in fatty acid activation,
carnitine-mediated transport and metabolim. As a ligand for
PPARc it is possible that rosiglitazone treatment also blocks
distinct effects of its endogenous fatty acid ligands. Alternatively,
since rosiglitazone is known to promote fat storage in some cell
types while down regulating FAO [56], rosiglitazone may activate
lipid storage rather than metabolism in the COC. The observation
of increased cumulus expansion in the presence of rosiglitazone
suggests that cumulus matrix production is increased, perhaps due
to increased carbohydrate metabolism in the face of impaired b-
oxidation. Indeed, elevated flux of glucose through the hexosa-
mine biosynthesis pathway has been shown to increase extracel-
lular matrix substrate supply and hence COC expansion [59].
Overall, these results indicate that compared to PPARa, PPARc is
a more active regulator of COC functions during oocyte
maturation.
We have previously demonstrated that in vivo administration of
rosiglitazone in obese mice significantly improved oocyte devel-
opmental competence [33]. What was unclear from this study
however is whether the effects of rosiglitazone on oocyte
developmental competence were due to direct effects on the
ovarian cells or via systemic effects such as reduced circulating
insulin and lipid. The results from the current study demonstrate
rosiglitazone action directly on the COC inhibited FAO and
impaired subsequent embryo development supporting the conclu-
sion that in vivo administration of rosiglitazone has indirect
beneficial effects on the oocyte via its actions on the maternal
systemic environment. These contradictory effects of rosiglitazone
on oocyte developmental competence might also be due to
differences in the availability of lipid substrate in the treated
COCs. We have previously shown that mice fed high fat diet
exhibit a marked increase in both oocyte and cumulus cell lipid
content compared to mice fed a low fat diet [60] and perhaps in
this cellular context rosiglitazone improves energy production and
embryo development; but has a negative effect when lipid levels
are limited.
Despite the negative effect of rosiglitazone on oocyte develop-
mental competence we found an increase in the inner mitochon-
drial membrane potential (MMP) of oocytes when COCs were
matured in the presence of rosiglitazone. An increase in MMP in
oocytes is usually associated with improved oocyte developmental
competence [61–63], although more recent reports have associ-
ated increased hyper-polarized mitochondria with decreased
oocyte developmental competence and increased embryo frag-
mentation [64,65]. Perhaps there is a threshold for a positive
association between MMP and oocyte developmental competence
and raising the MMP too high is detrimental due to excessive
levels of reactive oxygen species (ROS). How rosiglitazone raises
oocyte MMP despite significantly down-regulating FAO in the
whole COC is unclear but it is likely that rosiglitazone exerts cell
specific effects on cumulus cells and the oocyte, perhaps due to
differential receptor expression levels between these two cell types
and/or the presence of distinct co-activators.
From this and previous studies [17–20] it is emerging that FAO
is an important metabolic pathway in determining oocyte
developmental potential in vitro. We show here that FAO is
induced during oocyte maturation in vivo and is deficient during
IVM. The PPAR agonists bezafibrate and rosiglitazone were not
effective in restoring FAO in vitro. In conclusion, further
optimization of in vitro maturation conditions to normalize levels
of FAO to that observed in vivo may be necessary to improve the
success of IVM.
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